Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
Top Page
Nectar Lifesciences Ltd.
(NECLIFE)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹12.00
▼(-34.25% Downside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by inconsistent profitability and growth, plus a generally weak longer-term technical trend (below key moving averages and negative MACD). A relatively low P/E provides some support, but not enough to offset the financial and trend risks.
Positive Factors
Diversified manufacturing streams
Nectar operates across APIs, finished dosage forms and contract manufacturing, giving multiple durable revenue channels. This structural diversity supports capacity utilization, reduces reliance on a single end-market and helps capture value across the pharma supply chain over months to years.
Negative Factors
Severe revenue decline
A >50% year-on-year revenue contraction is a structural red flag: it compresses scale economics, raises per-unit fixed costs and limits reinvestment capacity. Persistent top-line decline undermines long-term margin recovery and makes consistent profit restoration harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified manufacturing streams
Nectar operates across APIs, finished dosage forms and contract manufacturing, giving multiple durable revenue channels. This structural diversity supports capacity utilization, reduces reliance on a single end-market and helps capture value across the pharma supply chain over months to years.
Read all positive factors
Nectar Lifesciences Ltd. (NECLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.65B
Dividend YieldN/A
Average Volume (3M)34.32K
Price to Earnings (P/E)7.6
Beta (1Y)1.13
Revenue Growth-30.27%
EPS Growth-3470.06%
CountryIN
Employees1,686
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.64
Shares Outstanding224,260,970
10 Day Avg. Volume25,321
30 Day Avg. Volume34,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.32
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nectar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validati...
How the Company Makes Money
Nectar Lifesciences makes money primarily by manufacturing and selling pharmaceutical products to customers such as drug marketers, wholesalers/distributors, and other pharmaceutical companies. Key revenue streams include: (1) Sale of finished dos...
Nectar Lifesciences Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.70B | 16.70B | 16.84B | 15.24B | 16.69B | 15.43B |
| Gross Profit | 671.45M | 3.02B | 4.82B | 579.91M | 2.99B | 2.58B |
| EBITDA | -1.71B | -245.66M | 1.69B | 994.97M | 1.61B | 612.51M |
| Net Income | -3.61B | -1.14B | 49.95M | -241.83M | 250.47M | -732.64M |
Balance Sheet | ||||||
| Total Assets | 18.15B | 20.47B | 21.91B | 21.89B | 23.91B | 23.88B |
| Cash, Cash Equivalents and Short-Term Investments | 139.72M | 272.63M | 203.01M | 178.94M | 182.35M | 259.58M |
| Total Debt | 4.59B | 5.82B | 6.36B | 7.54B | 8.60B | 9.03B |
| Total Liabilities | 10.98B | 10.91B | 11.22B | 11.25B | 13.03B | 13.26B |
| Stockholders Equity | 7.17B | 9.56B | 10.69B | 10.65B | 10.88B | 10.62B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | 1.26B | 1.95B | 1.04B | 700.35M | -98.62M |
| Operating Cash Flow | 1.53B | 1.69B | 2.25B | 1.34B | 950.05M | 213.79M |
| Investing Cash Flow | -82.31M | -419.30M | -170.25M | 517.04M | 166.44M | -286.24M |
| Financing Cash Flow | -1.58B | -1.28B | -2.05B | -1.86B | -1.19B | 114.90M |
Nectar Lifesciences Ltd. Technical Analysis
Neutral
18.25
Price Trends
12.02
Negative
14.99
Negative
15.62
Negative
Market Momentum
-0.43
Negative
58.93
Neutral
92.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Neutral. The current price of 18.25 is above the 20-day moving average (MA) of 10.62, above the 50-day MA of 12.02, and above the 200-day MA of 15.62, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 58.93 is Neutral, neither overbought nor oversold. The STOCH value of 92.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NECLIFE.
Nectar Lifesciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹13.29B | 10.01 | ― | ― | 13.32% | 218.38% | |
66 Neutral | ₹12.94B | 22.21 | ― | ― | 24.20% | 55.01% | |
65 Neutral | ₹11.51B | 18.86 | ― | ― | -37.70% | -19.79% | |
63 Neutral | ₹3.56B | 19.99 | ― | ― | -5.82% | -59.22% | |
55 Neutral | ₹3.29B | 56.53 | ― | 0.26% | -9.16% | 49.09% | |
52 Neutral | ₹2.65B | 7.63 | ― | ― | -30.27% | -3470.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:NECLIFE
Nectar Lifesciences Ltd.
11.82
-10.96
-48.11%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
141.05
54.67
63.29%
IN:MEDICAMEQ
Medicamen Biotech Limited
242.45
-250.07
-50.77%
IN:SAKAR
Sakar Healthcare Ltd
589.45
324.99
122.89%
IN:VENUSREM
Venus Remedies Limited
994.15
682.60
219.10%
IN:ZIMLAB
Zim Laboratories Ltd.
73.07
-14.93
-16.97%
Nectar Lifesciences Ltd. Corporate Events
Nectar Lifesciences Files SEBI Dematerialisation Compliance Certificate for Q4 FY26
Apr 6, 2026
Nectar Lifesciences Ltd. has notified the stock exchanges that it received a quarterly compliance certificate from its registrar and share transfer agent, KFin Technologies Ltd., under Regulation 74(5) of SEBI’s Depositories and Participants...
Nectar Lifesciences Shareholders Clear Key Board and Governance Changes via Postal Ballot
Mar 1, 2026
Nectar Lifesciences Ltd. has announced the results of a recent postal ballot, conducted via remote e-voting between January 30 and February 28, 2026, to seek shareholder approval on key corporate resolutions. Based on the scrutinizer’s repor...
Nectar Lifesciences Says Subsidiary Inactive, Standalone and Consolidated Results Aligned
Feb 10, 2026
Nectar Lifesciences has clarified to the National Stock Exchange that its only wholly owned subsidiary, NECLIFE PT, UNIPESSOAL LDA, recorded no business activity, revenue, or expenditure during the quarter ended September 30, 2025. As a result, th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.